Hanp-fc-containing molecular conjugate

A conjugate comprising a hANP peptide bonded via a polyethylene glycol linker (L(PEG)) to a glycan attached to Asn297 of a Fc-containing molecule (N297 glycan), or a pharmaceutically acceptable salt thereof, wherein:

• the hANP peptide optionally lacks 1 to 5 amino acids consecutively from the N terminus and/or one C terminal amino acid in the amino acid sequence represented by SEQ ID NO:
• 1 and is optionally glycosylated at either one or both of its N terminus and C terminus;
• the L(PEG) is a linker structure comprising 10 to 35 ethylene glycol structures and optionally comprising an additional binding structure and/or modifying structure;
• the Fc-containing molecule is a molecule having an amino acid sequence corresponding to a human IgG Fc region and having no ability to bind specifically to a human biomolecule;
• and
• the N297 glycan is a glycan N297-(Fuc)SG, N297-(Fuc)MSG1 or N297-(Fuc)MSG2 having a structure represented by the following formula:
• wherein L(PEG) represents binding to carbonyl groups bonded to the 2-positions of sialic acid residues at the non-reducing ends of both the 1-3 and 1-6 branched chains of β-Man,
• wherein L(PEG) represents binding to a carbonyl group bonded to the 2-position of a sialic acid residue at the non-reducing end of the 1-3 branched chain of β-Man, and
• wherein L(PEG) represents binding to a carbonyl group bonded to the 2-position of a sialic acid residue at the non-reducing end of the 1-6 branched chain of β-Man.